GlassScriptPhysician profile
Parry A Moore
NPI 1760467880
$5,643.37
in general payments reported to CMS, 2019-2025
39 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $754 · 2021: $984 · 2022: $144 · 2023: $439 · 2024: $838 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $638.55 | 2019-2024 | Breztri, Airsupra |
| Novo Nordisk INC | $494.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $482.96 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $462.99 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $447.98 | 2019-2025 | |
| Pfizer INC. | $394.26 | 2019-2025 | |
| Lilly USA, LLC | $331.24 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $298.43 | 2019-2025 | Shingrix, Arexvy |
| Eisai INC. | $254.75 | 2020-2025 | |
| Amarin Pharma, INC. | $243.49 | 2019-2021 | |
| Allergan, INC. | $238.51 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $144.47 | 2020-2021 | |
| Esperion Therapeutics, INC. | $143.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $99.87 | 2019-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $90.49 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $86.63 | 2021-2025 | Capvaxive, Gardasil 9 |
| Aimmune Therapeutics, INC. | $67.64 | 2024 | |
| Sanofi Pasteur INC. | $58.86 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.69 | 2023-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.04 | 2021-2025 | Jardiance |
| Abbott Laboratories | $44.12 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $39.70 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $36.30 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $32.99 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.72 | 2024-2025 | Caplyta |
| Medicure Pharma INC. | $30.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.77 | 2019-2020 | |
| Dexcom, INC. | $23.74 | 2025 | Dexcom G6 Transmitter |
| Aerin Medical INC. | $22.97 | 2025 | |
| Clarus Therapeutics INC. | $19.69 | 2021 | |
| Itamar Medical INC | $19.30 | 2023 | Watchpatone |
| Amneal Pharmaceuticals LLC | $18.32 | 2024 | Unithroid |
| Amphastar Pharmaceuticals, INC. | $17.75 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.69 | 2025 | Gvoke Hypopen |
| Acella Pharmaceuticals, LLC | $17.48 | 2024 | NP Thyroid 60 |
| Baxter Healthcare | $16.75 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $13.59 | 2025 | Intellis Adaptivestim |
| Medtronic USA, INC. | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parry Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.